Boston Scientific Co. (NYSE:BSX) EVP David A. Pierce sold 5,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $43.33, for a total transaction of $216,650.00. Following the completion of the transaction, the executive vice president now directly owns 29,201 shares in the company, valued at approximately $1,265,279.33. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
NYSE BSX opened at $43.01 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.77 and a current ratio of 1.14. The company has a market capitalization of $59.96 billion, a price-to-earnings ratio of 29.26, a price-to-earnings-growth ratio of 2.42 and a beta of 0.78. The company’s 50-day simple moving average is $41.28 and its two-hundred day simple moving average is $41.34. Boston Scientific Co. has a one year low of $31.56 and a one year high of $43.84.
Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.01. The business had revenue of $2.71 billion for the quarter, compared to the consensus estimate of $2.68 billion. Boston Scientific had a net margin of 10.49% and a return on equity of 23.10%. The company’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.35 EPS. Equities analysts expect that Boston Scientific Co. will post 1.57 earnings per share for the current fiscal year.
Several research analysts recently commented on BSX shares. Barclays reaffirmed an “overweight” rating and issued a $48.00 price target on shares of Boston Scientific in a research note on Tuesday, September 3rd. Morgan Stanley set a $50.00 price target on shares of Boston Scientific and gave the stock a “buy” rating in a research note on Thursday, August 29th. Raymond James reduced their price target on shares of Boston Scientific from $50.00 to $48.00 and set a “strong-buy” rating on the stock in a research note on Monday, October 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $53.00 price target on shares of Boston Scientific in a research note on Wednesday, October 23rd. Finally, Guggenheim set a $53.00 price target on shares of Boston Scientific and gave the stock a “buy” rating in a research note on Friday, October 25th. Two investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $47.19.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Story: How is diluted EPS different from basic EPS?
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.